^99mTc-ECD

Technetium (^99mTc) bicisate, also known as ^99mTc-ECD (ethyl cysteinate dimer) and marketed under the brand name Neurolite, is a radiopharmaceutical used in nuclear medicine for the assessment of regional cerebral blood flow (rCBF) by means of single-photon emission computed tomography (SPECT).^[1][2] It is a neutral, lipophilic complex of the metastable nuclear isomer technetium-99m with the ligand L,L-ethyl cysteinate dimer. After intravenous injection, ^99mTc-ECD readily crosses the blood–brain barrier and is taken up by brain tissue in proportion to blood flow. Its retention in the brain depends on intracellular esterase activity, which converts the lipophilic complex into a hydrophilic, charged metabolite that is trapped in cells.^[3] This mechanism provides stable images of cerebral perfusion, making ^99mTc-ECD a valuable tool for the evaluation of stroke, epilepsy, and neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies.^[4][5]

The development of ^99mTc-ECD traces back to fundamental research on technetium coordination chemistry and the search for improved brain perfusion imaging agents in the 1980s.^[6]

The ECD ligand (L,L-ethyl cysteinate dimer) belongs to the diamine dithiol (DADT) family of compounds. Its synthesis was first described by Blondeau et al. in 1967 as part of studies on the reduction of thiazolidine-4-carboxylic acid derivatives.^[7]

In the early 1980s, researchers began systematically investigating the coordination chemistry of technetium with various ligand systems, including DADT derivatives.^[6] The goal was to develop neutral, lipophilic complexes that could cross the intact blood–brain barrier and be retained in brain tissue long enough for SPECT imaging.^[3]

A key breakthrough came when investigators observed that certain ^99mTc-DADT complexes showed unexpectedly high and prolonged brain uptake in primates, but not in rodents.^[3] This species‑specific behavior led to the discovery that brain retention depended on metabolic conversion by intracellular esterases, a mechanism that was elucidated in the late 1980s and early 1990s.^[3] The work by Walovitch et al. established that hydrolysis of one ethyl ester group produced a charged, hydrophilic metabolite (^99mTc-ECM) that could not diffuse back across cell membranes, effectively trapping the tracer in primate brain tissue.^[3]

Following the elucidation of its mechanism, ^99mTc-ECD underwent extensive preclinical and clinical evaluation. Phase I and II studies in healthy volunteers and patients with various neurological disorders demonstrated its safety, favorable dosimetry, and ability to produce high‑quality perfusion images.^[1] The tracer was shown to have advantages over the existing agent ^99mTc-HMPAO in terms of in vitro stability and image contrast.^[8]

^99mTc-ECD received regulatory approval in several countries during the 1990s. In the United States, the Food and Drug Administration (FDA) approved the Neurolite® kit for marketing in 1994. European approval followed shortly thereafter, and the tracer was included in the European Pharmacopoeia.^[9]

Throughout the 1990s and 2000s, ^99mTc-ECD became widely adopted for clinical brain SPECT imaging. Its utility was demonstrated in a growing range of applications, including epilepsy localization,^[5] differential diagnosis of dementias,^[2][4] and assessment of cerebrovascular disease. Comparative studies with ^99mTc-HMPAO highlighted important differences between the two tracers, leading to a better understanding of their respective strengths and limitations.^[4][10]

In the 2000s and 2010s, research focused on refining quality control methods (e.g., using radio‑LC‑MS for identity confirmation)^[9] and on integrating ^99mTc-ECD SPECT with advanced image analysis techniques such as statistical parametric mapping (SPM) and SISCOM (subtraction ictal SPECT coregistered to MRI).^[5]

The ligand used in ^99mTc-ECD is L,L-ethyl cysteinate dimer (L,L-ECD), a member of the diamine dithiol (DADT) family of compounds.^[1] Its full chemical name is N,N′-1,2-ethylenediylbis-L-cysteine diethyl ester. The molecule contains two cysteine units linked by an ethylene bridge, with both cysteine residues in the L‑configuration; the terminal carboxylic acid groups are protected as ethyl esters. This L,L stereoisomer is essential for the biological behavior of the final technetium complex.^[3]

The synthesis of the ECD ligand was first described by Blondeau et al. in 1967 and involves the reduction of a thiazolidine‑4‑carboxylic acid derivative with sodium in liquid ammonia, leading to dimerization.^[7] A typical laboratory preparation, reported by the Office of Atomic Energy for Peace (Thailand), yields purified ECD dihydrochloride with an average yield of 22.8% (approximately 3.89 g per batch).^[1]

When technetium-99m (as pertechnetate, ^99mTcO₄⁻) is added to a vial containing the ECD ligand, stannous chloride (SnCl₂) reduces technetium from oxidation state +VII to a lower valence (most commonly +V). The reduced technetium then forms a neutral, lipophilic complex with the ECD ligand. In this complex, an oxotechnetium(V) core [Tc=O]³⁺ is chelated by two amine nitrogen atoms (one of which remains protonated) and two deprotonated thiol sulfur atoms, yielding a square‑pyramidal geometry.^[6][9] The ester groups remain intact during complexation, preserving the overall neutrality and lipophilicity required for blood–brain barrier passage.^[3]

The radiochemical purity of the final product is typically assessed by thin-layer chromatography (TLC), instant thin-layer chromatography (ITLC), and high-performance liquid chromatography (HPLC). Under optimized conditions, the radiochemical purity exceeds 95%, and the complex shows good in vitro stability for at least five hours after labeling.^[1] Mass spectrometric analysis (radio‑LC‑MS) has confirmed the expected molecular ion mass of the ^99mTc-ECD complex, providing direct proof of its identity.^[9]

The mechanism by which ^99mTc-ECD enables brain perfusion imaging involves two key steps: initial uptake proportional to blood flow and metabolic trapping that ensures prolonged retention in brain tissue.^[3]

After intravenous injection, the neutral and lipophilic ^99mTc-ECD complex readily crosses the intact blood–brain barrier by passive diffusion. Its first-pass extraction fraction is high (typically > 40%), meaning that a substantial proportion of the tracer delivered to the brain is taken up during a single capillary transit.^[3] The initial brain uptake is linearly related to regional cerebral blood flow (rCBF), which is the physiological basis for perfusion imaging.^[4]

Once inside brain cells, the tracer undergoes rapid enzymatic transformation. Cytoplasmic esterases hydrolyze one of the two ethyl ester groups of the ECD molecule, converting the neutral lipophilic complex into a charged, hydrophilic monoacid metabolite (^99mTc-ECM, N,N′-1,2-ethylenediylbis-L-cysteine monoethyl ester).^[3][9] This metabolite is no longer able to diffuse back across the cell membrane and becomes effectively trapped in the brain tissue. The trapping is selective for primate brain; in non‑primate species (rodents, dogs, pigs) the metabolism is much slower or absent, leading to rapid washout of the tracer and explaining the species‑dependent differences in brain retention observed during development.^[3]

A small fraction of the tracer may also undergo complete hydrolysis to the diacid form (^99mTc-EC), but the monoacid metabolite is the predominant retained species. The intact ester functions are therefore essential for the tracer's clinical utility; any premature hydrolysis (e.g., during kit preparation or storage) would compromise brain uptake.^[9]

Because the trapping mechanism depends on intracellular enzymatic activity, ^99mTc-ECD images reflect not only blood flow but also the integrity of cerebral parenchyma. In conditions where esterase activity is reduced (e.g., in some neurodegenerative processes), tracer retention may be altered independently of flow, a factor that must be considered when interpreting clinical images.^[4]

^99mTc-ECD is not supplied as a ready‑to‑inject solution but is prepared immediately before use from a sterile, lyophilized kit (marketed under the brand name Neurolite).^[9] Each vial typically contains the ECD ligand (as the dihydrochloride salt), stannous chloride as a reducing agent, a buffer (often phosphate or tartrate), and other excipients to stabilize the formulation.^[1][9]

The kit is reconstituted by adding a sterile solution of sodium pertechnetate (^99mTcO₄⁻) freshly eluted from a ⁹⁹Mo/^99mTc generator. The stannous ions reduce technetium from oxidation state +VII to a lower oxidation state (mainly +V), enabling it to chelate with the ECD ligand.^[6] The reaction proceeds at room temperature and is complete within 15–30 minutes, yielding a clear, colorless solution containing the neutral lipophilic ^99mTc-ECD complex.^[1]

Radiochemical purity (RCP) is the fraction of total ^99mTc activity present as the desired ^99mTc-ECD complex. Regulatory pharmacopoeias (e.g., European Pharmacopoeia, US Pharmacopeia) require RCP to exceed 90% (typically ≥95%) for human use.^[1] Several analytical methods are used to determine RCP:

• Thin-layer chromatography (TLC) and instant thin-layer chromatography (ITLC) are the most common quality control techniques because they are quick and easy to perform in a hospital radiopharmacy. Using appropriate mobile phases and solid phases, ^99mTc-ECD, free pertechnetate (^99mTcO₄⁻), and reduced‑hydrolyzed technetium (^99mTcO₂ colloid) migrate differently, allowing their separation and quantification;^[1]
• High-performance liquid chromatography (HPLC) with a radiometric detector provides more detailed information about the chemical species present. It can separate ^99mTc-ECD from potential impurities such as the partially hydrolyzed monoester (^99mTc-ECM) and the fully hydrolyzed diacid (^99mTc-EC), as well as from any residual pertechnetate.^[9] HPLC is the reference method for identity confirmation in the European Pharmacopoeia.^[9]

Potential radiochemical impurities include:^[9]

• Free pertechnetate (^99mTcO₄⁻): arises from incomplete reduction or oxidation of the complex;
• Reduced‑hydrolyzed technetium (^99mTcO₂ colloid): formed if the pH is unsuitable or if stannous ion concentration is excessive;
• Hydrolyzed products (^99mTc-ECM, ^99mTc-EC): result from ester cleavage of the ligand either during storage of the kit or after reconstitution.

After reconstitution, ^99mTc-ECD remains stable for several hours at room temperature. Studies have shown that radiochemical purity exceeds 90% for at least 5 hours post‑labeling.^[1] However, once drawn into a plastic syringe for injection, the tracer may show gradual degradation; therefore it is recommended to inject the dose within 30–60 minutes after drawing it up.^[8]

Modern analytical techniques. Radio‑LC‑MS (liquid chromatography–mass spectrometry coupled with radiometric detection) has been applied to confirm the identity of ^99mTc-ECD at the tracer level. This technique simultaneously measures the mass of the technetium complex (as the ⁹⁹Tc or ^99mTc species) and its radioactivity, providing unambiguous proof of structure.^[9]

^99mTc-ECD is indicated for the evaluation of regional cerebral perfusion in various neurological disorders. Its mechanism of metabolic trapping provides stable images that reflect cerebral blood flow at the time of injection, making it suitable for both ictal and interictal studies.

A prospective study comparing unstabilised ^99mTc-HMPAO with ^99mTc-ECD in 98 consecutive patients with partial epilepsy demonstrated several advantages of ^99mTc-ECD.^[5]

• Injection timing: The latency from seizure onset to injection was significantly shorter with ^99mTc-ECD (median 34 seconds) than with unstabilised ^99mTc-HMPAO (median 80 seconds; p < 0.0001). Consequently, the rate of truly postictal injections (i.e., injections occurring after seizure termination) was much lower in the ^99mTc-ECD group (16.3%) compared to the ^99mTc-HMPAO group (57.1%; p < 0.0001);^[5]
• Image quality: Quantitative analysis showed that ^99mTc-ECD images had significantly higher cortical/extracerebral uptake ratios (median 5.0 vs 3.6) and cortical/subcortical uptake ratios (median 2.5 vs 2.2) compared to unstabilised ^99mTc-HMPAO (both p < 0.005). These higher ratios reflect better target-to-background contrast;^[5]

These higher ratios reflect better target-to-background contrast.^[5]

• Localizing value: Subtraction of interictal from ictal SPECT images coregistered with MRI (SISCOM) was performed in patients for whom both studies were available. Blinded review of the SISCOM images localized the epileptic focus in a significantly higher proportion of patients studied with ^99mTc-ECD (40/45, 88.9%) than with unstabilised ^99mTc-HMPAO (25/37, 67.6%; p < 0.05). Moreover, the localization obtained with ^99mTc-ECD showed better concordance with electroencephalography (EEG), magnetic resonance imaging (MRI), and the final discharge diagnosis.^[5]

The authors concluded that ^99mTc-ECD compares favorably with unstabilised ^99mTc-HMPAO for peri-ictal SPECT studies. Its use results in earlier injections, fewer postictal injections, and improved image quality, thereby enhancing both the sensitivity and specificity of the technique for localizing epileptogenic foci in refractory partial epilepsy.^[5]

A study comparing ^99mTc-HMPAO and ^99mTc-ECD in 64 patients with mild to moderate AD found significant regional differences in tracer uptake.^{[4] 99m}Tc-ECD SPET gave significantly higher uptake ratio values than ^99mTc-HMPAO in several symmetrical clusters, including the occipital cuneus, the left occipital and parietal precuneus, and the left superior and middle temporal gyri. Conversely, ^99mTc-HMPAO SPET gave significantly higher uptake ratio values than ^99mTc-ECD in the hippocampus bilaterally. These findings indicate that in AD, the choice of tracer influences the perceived extent and topography of hypoperfusion, and underscore the need for tracer‑specific normative databases.^[4]

A retrospective study of 34 patients with probable DLB and 28 patients with probable AD evaluated the utility of ^99mTc-ECD SPECT for distinguishing between the two conditions.^[2]

• Patients with DLB had significantly lower perfusion indexes in the right and left occipital regions compared to AD patients (p = 0.004 and p = 0.005, respectively);
• Patients with AD had significantly lower perfusion in the left medial temporal region compared to DLB patients (p = 0.013).

Using these regional perfusion patterns, DLB was correctly identified with a sensitivity of 65% and a specificity of 71%. Notably, among DLB patients with visual hallucinations (26/34), bilateral occipital hypoperfusion was observed in 57.7%; none of the eight non‑hallucinating DLB patients showed occipital hypoperfusion (perfusion indexes ≥0.95). This finding supports a link between occipital dysfunction and the occurrence of visual hallucinations in DLB.^[2]

Interpretation of ^99mTc-ECD SPECT images requires knowledge of normal physiological variations. A study of 39 healthy adults (24 men, 15 women; mean age 52.6 ± 6.7 years) investigated age‑ and gender‑related perfusion using ^99mTc-ECD and voxel‑based statistical analysis (SPM99).^[10]

In the ^99mTc-ECD group, areas in the bilateral retrosplenial cortex showed decreasing perfusion with advancing age. No significant age‑related changes were observed in other cortical regions, and there were no substantial gender differences in perfusion patterns. Importantly, these age‑related changes differed from those observed with ^99mTc-HMPAO in a separate group of 45 healthy subjects, confirming that the two tracers are not interchangeable when studying subtle perfusion effects.^[10]

The pharmacokinetic behavior of ^99mTc-ECD has been characterized in both animal models and human subjects. Its distribution reflects the balance between flow‑dependent initial uptake and metabolism‑dependent retention.

After intravenous injection, ^99mTc-ECD is rapidly cleared from the bloodstream. In humans, approximately 5–6% of the injected dose is taken up by the brain within the first minute, corresponding to the high first‑pass extraction fraction (>40%).^[3] The remaining activity distributes throughout the body, with significant uptake in the lungs, liver, and intestines due to the lipophilicity of the tracer.^[1]

In non‑human primates, brain activity peaks within 2–5 minutes and remains stable for several hours owing to metabolic trapping.^[3] In rodents and other non‑primate species, brain retention is much lower because the esterase‑mediated conversion to the hydrophilic metabolite is inefficient, leading to rapid washout.^[3]

The primary metabolic pathway is hydrolysis of one ethyl ester group by cytoplasmic esterases, yielding the charged monoacid metabolite ^99mTc-ECM.^[3][9] A small fraction may undergo complete hydrolysis to the diacid ^99mTc-EC. In human plasma, the tracer is relatively stable, with most of the injected dose remaining as the parent complex during the first few minutes; metabolism occurs predominantly in the brain and, to a lesser extent, in the liver and kidneys.^[3]

The principal route of elimination is via the urinary system. Within 24 hours, about 50–60% of the injected radioactivity is excreted in the urine, predominantly as the hydrophilic metabolites ^99mTc-ECM and ^99mTc-EC.^[1] Hepatic clearance accounts for a smaller fraction, with some activity appearing in the faeces.^[1]

The effective dose equivalent for ^99mTc-ECD in adults is approximately 6–8 μSv/MBq, resulting in an effective dose of about 3–4 mSv for a typical administered activity of 500–800 MBq.^[1] The organs receiving the highest absorbed doses are the bladder wall (due to urinary excretion), the gallbladder wall, and the intestines.^[1]

Any condition that alters cerebral esterase activity (e.g., severe ischemia, neurodegenerative disease) may affect tracer retention independently of blood flow.^[4]

⁹⁹Tc-ECD is considered a safe radiopharmaceutical when used in accordance with the recommended procedures and precautions. Its safety profile is based on clinical studies, post‑marketing surveillance, and the inherent characteristics of the technetium‑99m label.^[1]

Serious adverse effects associated with ⁹⁹ᐧTc-ECD are rare. The most commonly reported reactions are mild and transient, including headache, dizziness, nausea, flushing, and injection site discomfort.^[2] Hypersensitivity reactions (rash, urticaria, pruritus) occur in less than 1% of patients. Anaphylactic reactions are exceedingly rare but have been described.^[9]

As with all radiopharmaceuticals, ⁹⁹ᐧTc-ECD exposes patients to ionizing radiation. The effective dose for an adult receiving a typical administered activity of 740 MBq (20 mCi) is approximately 5.2 mSv.^[1] This dose is comparable to that of other common ⁹⁹ᐧTc‑labeled brain perfusion agents. The critical organs are the bladder wall, gallbladder wall, and lower large intestine.^[1]

The only absolute contraindication is known hypersensitivity to any component of the preparation. Pregnancy is a relative contraindication; the tracer should be administered to pregnant women only if the potential benefit justifies the radiation risk to the fetus.^[10]

No clinically significant drug interactions have been conclusively documented. However, drugs that affect cerebral blood flow (e.g., acetazolamide, vasoactive substances) or that alter esterase activity could theoretically influence tracer uptake and retention.^[4]

Standard radiation safety precautions for handling radiopharmaceuticals should be observed. The preparation should be inspected visually for particulate matter or discoloration before administration. As with all injectable products, aseptic technique must be maintained throughout the preparation and administration process.^[8]

Safety and effectiveness in children have not been established by rigorous clinical trials, but the tracer has been used off‑label in pediatric populations for conditions such as epilepsy.^[5] No age‑related adjustments to the administered activity are generally required, although the dose should be scaled according to body weight if used in children. In elderly patients, no special precautions are needed beyond those applicable to adults.^[10]

Several radiopharmaceuticals are available for the assessment of regional cerebral blood flow using SPECT. The most common alternative to ^99mTc-ECD is ^99mTc-hexamethylpropylene amine oxime (HMPAO, also known as exametazime). The two tracers differ in their chemistry, pharmacokinetics, and clinical behavior, which has implications for image interpretation and diagnostic accuracy.^[4]

A practical advantage of ^99mTc-ECD is its superior in vitro stability after reconstitution. While unstabilised ^99mTc-HMPAO must be injected within 30 minutes of preparation to avoid degradation, ^99mTc-ECD remains stable for at least 5 hours at room temperature.^[1][8] Stabilised formulations of HMPAO have been developed to overcome this limitation, but they are not universally available.^[8]

Both tracers cross the blood–brain barrier because they are neutral and lipophilic. However, their retention mechanisms differ. ^99mTc-HMPAO is retained through conversion to a hydrophilic species by reaction with glutathione or other intracellular agents, a process that is less dependent on enzymatic activity.^[3] In contrast, ^99mTc-ECD retention requires active esterase-mediated hydrolysis, which shows species specificity (high in primates, low in rodents) and may be affected by the metabolic state of brain tissue.^[3]

Quantitative comparisons in healthy subjects and patients have shown that ^99mTc-ECD typically yields higher cortical-to-subcortical and cortical-to-extracerebral uptake ratios than unstabilised ^99mTc-HMPAO, resulting in better image contrast.^[5] This advantage is particularly evident in peri-ictal SPECT studies for epilepsy, where ^99mTc-ECD images showed superior target-to-background ratios and improved localizing value.^[5]

Several studies have demonstrated that the two tracers produce different relative uptake patterns in both normal and diseased brains. In healthy adults, age‑related perfusion changes appear in different regions depending on whether ^99mTc-ECD or ^99mTc-HMPAO is used.^[10] In Alzheimer's disease, ^99mTc-ECD shows relatively higher uptake than HMPAO in the occipital cortex and precuneus, but lower uptake in the hippocampus.^[4]

Clinical performance in specific indications. The choice of tracer may influence diagnostic accuracy in certain conditions:

• In epilepsy, ^99mTc-ECD allows significantly earlier injections during seizures and produces images with better contrast, leading to higher rates of focus localization compared to unstabilised HMPAO;^[5]
• In dementia with Lewy bodies, ^99mTc-ECD has been shown to detect occipital hypoperfusion that correlates with visual hallucinations, aiding differential diagnosis from Alzheimer's disease;^[2]
• In cerebrovascular disease, the dependence of ^99mTc-ECD retention on esterase activity may complicate the interpretation of acetazolamide challenge studies, as reduced enzyme function in chronically hypoperfused tissue could mimic impaired vascular reserve.^[4]

The effective dose per unit administered activity is similar for both tracers (approximately 6–8 μSv/MBq).^[1] However, the biodistribution differs slightly; ^99mTc-ECD shows higher initial lung and liver uptake, while ^99mTc-HMPAO has greater excretion through the hepatobiliary system.^[1]